ADVANCED LUNG NON-SMALL CELL CARCINOMA
Clinical trials for ADVANCED LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Common painkiller may help immunotherapy fight lung cancer
Disease control Recruiting nowThis study tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control tumor growth in people with advanced lung cancer whose disease is starting to worsen on immunotherapy alone. About 20 adults with stage III or IV non-small cell lung cancer will re…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
New hope for seniors with lung cancer: ACHIEVE trial tests combo therapy
Disease control Recruiting nowThis study looks at whether adding chemotherapy to immunotherapy (pembrolizumab) helps older adults (70+) with advanced non-small cell lung cancer live longer compared to immunotherapy alone. About 304 participants will receive either the combination or just immunotherapy. The go…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
New hope for advanced lung cancer: drug combo trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug (MRX-2843) combined with a standard treatment (osimertinib) for people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest and most effective dose and to see how well the combination works. About 69 particip…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 05:46 UTC
-
New hope for stubborn lung cancer: drug duo targets genetic mutation
Disease control Recruiting nowThis study tests a new drug combination (GT103 plus pembrolizumab) for people with advanced non-small cell lung cancer that has a specific genetic change called STK11 mutation. The goal is to see if adding GT103 can help shrink tumors or slow the cancer's growth. About 28 adults …
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New hope for Hard-to-Treat lung cancer: targeted pill shows promise
Disease control Recruiting nowThis study tests a pill called osimertinib in people with advanced lung cancer that has a specific genetic change (EGFR exon 20 insertion). The drug works by blocking signals that help cancer cells grow. About 46 participants will take the pill daily to see if it shrinks tumors o…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New combo targets hard-to-treat lung cancer in early trial
Disease control Recruiting nowThis early-phase study tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 15 adults who have already tried a KRAS inhibitor will receive the combinat…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Morning or afternoon? new study tests best time for cancer immunotherapy
Symptom relief Recruiting nowThis study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated May 26, 2026 05:51 UTC
-
Scientists hunt for hidden subtypes of cancer wasting to personalize treatment
Knowledge-focused Recruiting nowThis study watches 800 people with advanced lung, pancreatic, or colorectal cancer to find different types of cancer-related weight and muscle loss (cachexia). Researchers hope to discover why some patients lose weight differently than others. The goal is to create better, more p…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated May 26, 2026 05:57 UTC